Newron Pharmaceuticals - Moving towards R&D inflection points
Newron’s FY18 highlights the steady progression of its CNS R&D pipeline. STARS the pivotal Phase II/III (Sarizotan for Rett’s Syndrome) has completed enrolment and data are expected in Q419. Newron is planning to apply for a global filing and approval strategy once data are available. Evenamide (schizophrenia), developed internally through Newron’s ion channel discovery platform, could enable a paradigm shift in the treatment of refractory schizophrenia patients; in Q219 Newron will initiate two pivotal Phase IIb/III trials. We value Newron at CHF714m.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.